Tricida, Inc. (TCDA): Price and Financial Metrics


Tricida, Inc. (TCDA): $4.91

-0.01 (-0.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TCDA Stock Price Chart Interactive Chart >

Price chart for TCDA

TCDA Price/Volume Stats

Current price $4.91 52-week high $28.18
Prev. close $4.92 52-week low $3.74
Day low $4.88 Volume 139,300
Day high $5.03 Avg. volume 564,318
50-day MA $4.76 Dividend yield N/A
200-day MA $6.89 Market Cap 246.84M

Tricida, Inc. (TCDA) Company Bio


Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.


TCDA Latest News Stream


Event/Time News Detail
Loading, please wait...

TCDA Latest Social Stream


Loading social stream, please wait...

View Full TCDA Social Stream

Latest TCDA News From Around the Web

Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zoom, Capital One, and Tricida on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Zoom Video Communications, Inc. (NASDAQ: ZM), Capital One (NYSE: COF), and Tricida, Inc. (NASDAQ: TCDA) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Zoom Video Communications, Inc. (NASDAQ: ZM) Bragar Eagel & Squire is investigating certain officers and

Yahoo | June 4, 2021

Shareholder Alert: Robbins LLP is Investigating Tricida, Inc. (TCDA) for Shareholders

Shareholder rights law firm Robbins LLP is investigating Tricida, Inc. (NASDAQ: TCDA) to determine whether certain Tricida officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Tricida is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of non-absorbed therapies. Its lead drug candidate veverimer (TRC101) is intended to slow the progression of chronic kidney disease ("CKD") th

Yahoo | June 3, 2021

Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR

Yahoo | June 2, 2021

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Uniti Group, Surgalign Holdings, Tyson Foods, and Tricida on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Uniti Group, Inc. (NASDAQ: UNIT), Surgalign Holdings, Inc. (f/k/a RTI Surgical Holdings, Inc.) (Nasdaq: SRGA), Tyson Foods (NYSE: TSN), and Tricida, Inc. (NASDAQ: TCDA) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. Uniti Group, Inc. (NASDAQ: UNIT) Bragar Eagel & Squire is is investigating certain officers and directors of Uniti Group, Inc. following news that the Shareholder Class Action Against Uniti Group has survived the motions to dismiss in the pending securities class action and may face damages. The complaint alleges that Uniti made mate...

Yahoo | April 10, 2021

Tricida to Present at the Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation. About Tricida Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is c...

Yahoo | April 8, 2021

Read More 'TCDA' Stories Here

TCDA Price Returns

1-mo 5.59%
3-mo -3.16%
6-mo -36.81%
1-year -80.77%
3-year N/A
5-year N/A
YTD -30.35%
2020 -81.32%
2019 60.05%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7708 seconds.